Regions of papilloma virus e1 helicase involved in e1 oligomerization
CA 2335230 C · Owner: Boehringer Ingelheim (Canada) Ltd. · Inventors: Archambault, Jacques
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
There is provided an amino acid sequence comprised within the PV E1 protein region A delineated by amino acids 352 and 439 and any derivative variant or , fragment thereof necessary for the oligomerization of the E1 protein. This amino acid sequence is capable of self-association and of associating with the full length E1 protein and any derivative variant or fragment thereof , comprising the sequence of this invention. A specific aspect of this first embodiment, the amino acid domain of this invention delimited by amino acids 353 to 438 of the PV E1 protein. More particularly the amino acid domain of , this invention is as defined by SEQ ID NO. 2. There is also provided a crosslinking …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed July 30, 1999 and granted September 6, 2011. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended July 30, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 30, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.